MA28653B1 - Nouveaux derives fluoroglycosidiques des pyrazoles, les medicaments contenant ces composes et leur utilisation - Google Patents

Nouveaux derives fluoroglycosidiques des pyrazoles, les medicaments contenant ces composes et leur utilisation

Info

Publication number
MA28653B1
MA28653B1 MA29515A MA29515A MA28653B1 MA 28653 B1 MA28653 B1 MA 28653B1 MA 29515 A MA29515 A MA 29515A MA 29515 A MA29515 A MA 29515A MA 28653 B1 MA28653 B1 MA 28653B1
Authority
MA
Morocco
Prior art keywords
compounds
pyrazoles
new
products containing
medicinal products
Prior art date
Application number
MA29515A
Other languages
English (en)
Inventor
Harm Brummerhop
Wendelin Frick
Heiner Glombik
Oliver Plettenburg
Martin Bickel
Hubert Heuer
Stefan Theis
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of MA28653B1 publication Critical patent/MA28653B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)

Abstract

Nouveaux dérivés fluoroglycosidiques des pyrazoles, les médicaments contenant ces composés et leur utilisation. L'invention concerne des dérivés fluoroglycosidiques substitués des pyrazoles de formule (I), dans laquelle les radicaux ont les significations indiquées, les sels physiologiquement compatibles de ceux-ci, et une méthode de production de ceux-ci. Les composés conviennent par exemple en tant qu'antidiabétiques.
MA29515A 2004-06-11 2006-12-05 Nouveaux derives fluoroglycosidiques des pyrazoles, les medicaments contenant ces composes et leur utilisation MA28653B1 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102004028241A DE102004028241B4 (de) 2004-06-11 2004-06-11 Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel

Publications (1)

Publication Number Publication Date
MA28653B1 true MA28653B1 (fr) 2007-06-01

Family

ID=35355753

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29515A MA28653B1 (fr) 2004-06-11 2006-12-05 Nouveaux derives fluoroglycosidiques des pyrazoles, les medicaments contenant ces composes et leur utilisation

Country Status (34)

Country Link
US (1) US7820804B2 (fr)
EP (1) EP1758914B1 (fr)
JP (1) JP4996464B2 (fr)
CN (1) CN100582116C (fr)
AR (1) AR049393A1 (fr)
AU (1) AU2005252329B2 (fr)
BR (1) BRPI0510770A (fr)
CA (1) CA2570042C (fr)
CR (1) CR8773A (fr)
CY (1) CY1107426T1 (fr)
DE (2) DE102004028241B4 (fr)
DK (1) DK1758914T3 (fr)
EC (1) ECSP067054A (fr)
ES (1) ES2296180T3 (fr)
HK (1) HK1100411A1 (fr)
HR (1) HRP20080023T3 (fr)
IL (1) IL179757A (fr)
MA (1) MA28653B1 (fr)
MX (1) MXPA06013513A (fr)
MY (1) MY143565A (fr)
NO (1) NO20070176L (fr)
NZ (1) NZ551948A (fr)
PE (1) PE20060297A1 (fr)
PL (1) PL1758914T3 (fr)
PT (1) PT1758914E (fr)
RS (1) RS50541B (fr)
RU (1) RU2370499C2 (fr)
SI (1) SI1758914T1 (fr)
TN (1) TNSN06409A1 (fr)
TW (1) TWI382030B (fr)
UA (1) UA89787C2 (fr)
UY (1) UY28955A1 (fr)
WO (1) WO2005121161A1 (fr)
ZA (1) ZA200608832B (fr)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
DE102005026762A1 (de) 2005-06-09 2006-12-21 Sanofi-Aventis Deutschland Gmbh Azolopyridin-2-on-derivate als Inhibitoren von Lipasen und Phospholipasen
PE20110235A1 (es) 2006-05-04 2011-04-14 Boehringer Ingelheim Int Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
JP5067644B2 (ja) 2006-05-19 2012-11-07 大正製薬株式会社 Ｃ−フェニルグリシト−ル化合物
CN101479254B (zh) 2006-06-29 2012-05-30 大正制药株式会社 C-苯基1-硫代山梨醇化合物
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
DE102006053637B4 (de) 2006-11-14 2011-06-30 Sanofi-Aventis Deutschland GmbH, 65929 Neue mit Fluor substituierte 1,4-Benzothiepin-1,1-Dioxidderivate, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
WO2008072726A1 (fr) 2006-12-14 2008-06-19 Taisho Pharmaceutical Co., Ltd. Dérivé de 1-phényl 1-thio-d-glucitol
EP2025674A1 (fr) 2007-08-15 2009-02-18 sanofi-aventis Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
JP5272395B2 (ja) * 2007-12-12 2013-08-28 セントラル硝子株式会社 ４−デオキシ−４−フルオロ−ｄ−グルコース誘導体の製造方法
TW201014822A (en) 2008-07-09 2010-04-16 Sanofi Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
BRPI0918841B8 (pt) * 2008-08-28 2021-05-25 Pfizer derivados de dioxa-biciclo[3.2.1]octano-2,3,4-triol, seus cristais, composições farmacêuticas e usos
WO2010068601A1 (fr) 2008-12-08 2010-06-17 Sanofi-Aventis Hydrate de fluoroglycoside hétéroaromatique cristallin, ses procédés de fabrication, ses procédés d'utilisation et compositions pharmaceutiques le contenant
TWI460187B (zh) 2009-02-23 2014-11-11 大正製藥股份有限公司 ４－異丙基苯基葡萄糖醇化合物
CN102482312A (zh) * 2009-08-26 2012-05-30 赛诺菲 新颖的杂芳族氟代糖苷结晶水合物、含有这些化合物的药物和它们的用途
EP2298782A1 (fr) 2009-08-26 2011-03-23 Sanofi-Aventis Procédé de synthèse de dérivé de type pyrazole glucoside
KR20120091174A (ko) 2009-10-02 2012-08-17 사노피 골질환 치료제의 제조를 위한 ｓｇｌｔ-1/ｓｇｌｔ-2 억제제 활성을 갖는 화합물의 용도
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
AP3099A (en) 2009-11-02 2015-01-31 Pfizer Dioxa-bicyclo[3.2.1]octane-2,3,4-triol de derivatives
US20120294936A1 (en) 2009-11-13 2012-11-22 Astrazeneca Uk Limited Reduced mass metformin formulations
ES2689107T3 (es) 2009-11-13 2018-11-08 Astrazeneca Ab Formulaciones de tabletas bicapa
JP5784623B2 (ja) 2009-11-13 2015-09-24 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 速放性錠剤製剤
WO2011107494A1 (fr) 2010-03-03 2011-09-09 Sanofi Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
EP2582709B1 (fr) 2010-06-18 2018-01-24 Sanofi Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
JP5656092B2 (ja) 2010-08-20 2015-01-21 大正製薬株式会社 ４−イソプロピルフェニルグルシトール化合物の結晶形及びその製造方法
US9161945B2 (en) 2010-08-20 2015-10-20 Taisho Pharmaceutical Co., Ltd. 4-isopropyl-6-methoxyphenyl glucitol compound
AU2011295837B2 (en) 2010-09-03 2015-06-18 Astrazeneca Uk Limited Drug formulations using water soluble antioxidants
WO2012106303A1 (fr) 2011-02-01 2012-08-09 Bristol-Myers Squibb Company Formulations pharmaceutiques comprenant un composé amine
WO2012120052A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
WO2012120050A1 (fr) 2011-03-08 2012-09-13 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, médicaments contenant ces composés et leur utilisation
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683703B1 (fr) 2011-03-08 2015-05-27 Sanofi Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, agent pharmaceutique contenant ces composés et leur utilisation
EP2683704B1 (fr) 2011-03-08 2014-12-17 Sanofi Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
EP2683699B1 (fr) 2011-03-08 2015-06-24 Sanofi Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
US8828994B2 (en) 2011-03-08 2014-09-09 Sanofi Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120058A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
WO2012120051A1 (fr) 2011-03-08 2012-09-13 Sanofi Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
US8614195B2 (en) * 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
WO2013037390A1 (fr) 2011-09-12 2013-03-21 Sanofi Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
EP2760862B1 (fr) 2011-09-27 2015-10-21 Sanofi Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
UA113086C2 (xx) 2012-05-10 2016-12-12 Піразольні сполуки як інгібітори sglt1
TW201425326A (zh) 2012-10-05 2014-07-01 Lilly Co Eli 新穎脲化合物
AU2014213251B2 (en) 2013-02-04 2017-07-20 Taisho Pharmaceutical Co., Ltd. Prophylactic or therapeutic drug for constipation
EP2774619B1 (fr) 2013-03-04 2016-05-18 BioActive Food GmbH Composition pour le traitement de pathologies hyperglycémiques
AR098670A1 (es) 2013-11-08 2016-06-08 Lilly Co Eli Inhibidor de sglt1
EP2944311A1 (fr) 2014-05-16 2015-11-18 BioActive Food GmbH Combinaison de substances biologiques actives destinée au traitement de pathologies hypoglycémiques
MX2020010433A (es) * 2018-04-04 2020-10-28 Japan Tobacco Inc Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos.
WO2020113094A1 (fr) 2018-11-30 2020-06-04 Nuvation Bio Inc. Composés pyrrole et pyrazole et leurs procédés d'utilisation

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU719726B2 (en) * 1996-12-26 2000-05-18 Tanabe Seiyaku Co., Ltd. Propiophenone derivatives and process for preparing the same
TR200201082T2 (tr) * 1999-08-31 2002-07-22 Kissei Pharmaceutical Co., Ltd. Glikopriranoziloksipirazol türevleri
PH12000002657B1 (en) * 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
WO2002036602A1 (fr) * 2000-11-02 2002-05-10 Ajinomoto Co., Inc. Nouveaux derives du pyrazole et remedes au diabete contenant ces derniers
WO2002064839A2 (fr) * 2001-02-14 2002-08-22 Tularik Inc. Gene amplifie de l'hepsine associee au cancer
RU2356906C2 (ru) * 2002-08-08 2009-05-27 Киссеи Фармасьютикал Ко., Лтд. Производные пиразола, лекарственные композиции, содержащие эти производные, их применение в медицине и промежуточные соединения для их получения
JP2004137245A (ja) * 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
AU2003262262A1 (en) * 2002-08-27 2004-03-19 Kissei Pharmaceutical Co., Ltd. Pyrazole derivatives, medicinal composition containing the same, and medicinal use thereof
AU2003272903A1 (en) * 2002-10-04 2004-04-23 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof and intermediate in producing the same
AU2003289156A1 (en) * 2002-12-04 2004-06-23 Kissei Pharmaceutical Co., Ltd. Preventive or remedy for diseases caused by hyperglycemia
DE10258008B4 (de) * 2002-12-12 2006-02-02 Sanofi-Aventis Deutschland Gmbh Heterocyclische Fluorglycosidderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zur Herstellung dieser Arzneimittel
WO2004113359A1 (fr) * 2003-06-20 2004-12-29 Kissei Pharmaceutical Co., Ltd. Derive de pyrazole, composition de medicaments contenant ledit derive et intermediaire de production associe

Also Published As

Publication number Publication date
ES2296180T3 (es) 2008-04-16
RU2007101154A (ru) 2008-07-20
CN100582116C (zh) 2010-01-20
AU2005252329B2 (en) 2011-02-10
PT1758914E (pt) 2008-01-31
PE20060297A1 (es) 2006-05-25
CN1964984A (zh) 2007-05-16
PL1758914T3 (pl) 2008-04-30
HK1100411A1 (en) 2007-09-21
CR8773A (es) 2008-02-28
BRPI0510770A (pt) 2007-11-20
TWI382030B (zh) 2013-01-11
WO2005121161A1 (fr) 2005-12-22
UA89787C2 (ru) 2010-03-10
IL179757A0 (en) 2007-05-15
MXPA06013513A (es) 2007-03-01
DE502005002056D1 (de) 2008-01-03
DE102004028241A1 (de) 2006-01-05
EP1758914B1 (fr) 2007-11-21
SI1758914T1 (sl) 2008-04-30
TNSN06409A1 (en) 2008-02-22
AR049393A1 (es) 2006-07-26
HRP20080023T3 (en) 2008-06-30
UY28955A1 (es) 2006-01-31
RU2370499C2 (ru) 2009-10-20
US20070197623A1 (en) 2007-08-23
MY143565A (en) 2011-05-31
ZA200608832B (en) 2008-05-28
AU2005252329A1 (en) 2005-12-22
CA2570042C (fr) 2013-01-15
EP1758914A1 (fr) 2007-03-07
RS50541B (sr) 2010-05-07
CA2570042A1 (fr) 2005-12-22
IL179757A (en) 2010-12-30
NO20070176L (no) 2007-03-09
US7820804B2 (en) 2010-10-26
DK1758914T3 (da) 2008-03-17
JP2008501745A (ja) 2008-01-24
NZ551948A (en) 2010-04-30
ECSP067054A (es) 2007-01-26
JP4996464B2 (ja) 2012-08-08
DE102004028241B4 (de) 2007-09-13
TW200610527A (en) 2006-04-01
CY1107426T1 (el) 2012-12-19

Similar Documents

Publication Publication Date Title
MA28653B1 (fr) Nouveaux derives fluoroglycosidiques des pyrazoles, les medicaments contenant ces composes et leur utilisation
MA27559A1 (fr) Nouveaux derives de fluorglycoside aromatiques, produits pharmaceutiques contenant ces composes et leur utilisation
MA27560A1 (fr) Nouveaux derives de fluorglycoside heterocycliques, produits pharmaceutiques contenant ces composes et leur utilisation
MA30609B1 (fr) Imidazolidine-2,4-diones arylaminoaryl-alkyl-substituees, leur procede de synthese, les medicaments comprenant ces composes, et leurs applications.
TNSN01077A1 (fr) Derives de tropane nouveaux, procede pour leur preparation et compositions les contenant
MA27735A1 (fr) Heterocycles de n-aryle substitues, procede pour leur preparation et leur utilisation en tant que medicaments
EA200301306A1 (ru) Производные 1-фенилсульфонил-1,3-дигидро-2h-индол-2-она, их получение и их терапевтическое применение
CN101374807B (zh) 用于抑制bcl蛋白与结合配偶体的相互作用的化合物和方法
MA27867A1 (fr) Nouveaux derives de 2h-pyridazine-3-one, compositions pharmaceutiques contenant ces derives et procede de preparation de l'ingredient actif.
CA2944211C (fr) Compositions et methodes pour traiter des maladies neurodegeneratives
CN113801073B (zh) 14-氯-β-榄香烯一氧化氮供体型衍生物及其制备和应用
TNSN00250A1 (fr) Composes nouveaux inhibiteurs de pcp, procede pour leur preparation et compositions les contenant
TNSN02036A1 (fr) Derives d'acide 3- heterocyclylpropano-hydroxamique nouveaux, et compositions les contenant.
KR930000483A (ko) [(아릴알킬피페리딘-4-일)메틸]-2a,3,4,5-테트라 하이드로-1(2H)-아세나프틸렌-1-온 및 관련 화합물, 이의 제조방법 및 약제로서의 이의 용도
MA27657A1 (fr) Derives substitues du 3-(benzoylureido) thiophene, leur procede de preparation et leur utilisation
MA27963A1 (fr) Nouveaux derives de benzothiazine et benzothiadiazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
MA28026A1 (fr) Thiénoimidazoles substitués, procédé de production et utilisation de ceux-ci comme médicament ou agent de diagnostic, et médicaments les comprenant
MA28325A1 (fr) Nouveaux derives de phenylpyridinylpiperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN101300243A (zh) 邻位取代苯胺衍生物和抗氧化药
UA90290C2 (ru) Производные спирокеталов и их применение в качестве лекарственного средства против диабета
CA2670468A1 (fr) Derives de melatonine utilises comme antioxydants
FR2859208B1 (fr) Nouveaux derives de 9-amino-podophyllotoxine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
BRPI0413101A (pt) compostos de sulfonamida derivado de benzoxazinona, sua preparação e uso como medicamentos
WO2006088080A1 (fr) DÉRIVÉ DE CYCLOHEPTA[b]PYRIDINE-3-CARBONYLGUANIDINE ET PRODUITS PHARMACEUTIQUES CONTENANT LEDIT DÉRIVÉ
US20240101584A1 (en) Targeted delivery of 1,2,4,5 tetraoxane compounds and their uses